SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler
293
26. Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters,Fibroblast Growth Factor-21, and Cytokeratin-18.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
, cilt.36, sa.3, ss.152-161, 2025 (SCI-Expanded)
81. Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
, cilt.20, ss.2296-2312, 2022 (SCI-Expanded)
86. Lean non-alcoholic fatty liver disease patients from the global NASH registry
JOURNAL OF HEPATOLOGY
, cilt.77, 2022 (SCI-Expanded)
101. FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY
HEPATOLOGY
, cilt.74, 2021 (SCI-Expanded)
109. FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, ss.172, 2021 (SCI-Expanded)
135. Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.31, sa.12, ss.1601-1602, 2019 (SCI-Expanded)
136. Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES
, cilt.29, sa.6, ss.548, 2019 (SCI-Expanded)
157. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.28, sa.11, ss.1264-1267, 2016 (SCI-Expanded)
159. The role of active brown adipose tissue in human metabolism
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
, cilt.43, sa.2, ss.355-361, 2016 (SCI-Expanded)
161. Is NAFLD different in absence of metabolic syndrome?
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE
, ss.44-49, 2016 (SCI-Expanded)
162. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.27, sa.10, ss.1149-1153, 2015 (SCI-Expanded)
208. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
, cilt.71, sa.8, ss.631-636, 2011 (SCI-Expanded)
234. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease
Scandinavian Journal of Clinical and Laboratory Investigation
, cilt.70, ss.541-546, 2010 (SCI-Expanded)
246. Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis
GASTROENTEROLOGY
, cilt.138, sa.5, 2010 (SCI-Expanded)
247. C-KIT Gene Polymorphism in Achalasia
GASTROENTEROLOGY
, cilt.138, sa.5, 2010 (SCI-Expanded)
259. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.
American journal of reproductive immunology (New York, N.Y. : 1989)
, cilt.62, sa.4, ss.238-42, 2009 (SCI-Expanded)
Diğer Dergilerde Yayınlanan Makaleler
34
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
133
1. Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced primary biliary cholangitis
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, (Özet Bildiri)
4. Impact of weekend warrior physical activity on all-cause mortality in metabolic dysfunction-associated steatotic liver disease
EASL Congress 2025, Amsterdam, Hollanda, 07 Şubat 2025, (Tam Metin Bildiri)
5. VALIDATION OF AND MECHANISTIC INSIGHTS ON A BILE ACID SIGNATURE OF FIBROSIS PROGRESSION IN METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, (Özet Bildiri)
6. THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, cilt.80, (Özet Bildiri)
7. VALIDATION OF MICROBIAL SIGNATURE FOR ADVANCED FIBROSIS IN A GLOBAL MULTI-ETHNIC COHORT OF MASLD
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, (Özet Bildiri)
31. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?
International Liver Congress, ELECTR NETWORK, 23 - 26 Haziran 2021, cilt.75, (Özet Bildiri)
36. THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
37. SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
38. PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
39. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
47. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)
49. THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)
55. Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri)
56. Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients
Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portekiz, 23 - 26 Mayıs 2018, cilt.102, ss.304-305, (Özet Bildiri)
61. Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri)
62. Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri)
68. Hepatit C Tedavilerinin İlaç Etkileşimleri
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017, (Özet Bildiri)
73. Obezite ve yağlı karaciğer
7. Ulusal Obezite Kongresi, İstanbul, Türkiye, 8 - 11 Aralık 2016
83. Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study
EASL monothematic conference 2016, Riga, Letonya, 12 - 14 Mayıs 2016, (Özet Bildiri)
86. Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015
93. Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması
BUHASDER 6.Tepecik Enfeksiyon Günleri Sempozyumu, Muğla, Türkiye, 4 - 08 Kasım 2015
97. Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri)
105. Otoimmün hepatit ilaç hepatotoksisitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem
A’dan Z’ye Psöriazis Toplantısı, İstanbul, Türkiye, 08 Kasım 2014
118. Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri)
123. HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDECAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, (Özet Bildiri)
128. Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler
4. Hepatoloji Okulu, Muğla, Türkiye, 25 - 26 Mayıs 2012
130. Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis
Conference on Digestive Disease Week 2011, Illinois, Amerika Birleşik Devletleri, 7 - 10 Mayıs 2011, cilt.140, (Özet Bildiri)
131. SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, (Özet Bildiri)
132. CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, (Özet Bildiri)
Kitaplar
13
Metrikler
Yayın
478
Açık Erişim
28
BM Sürdürülebilir Kalkınma Amaçları
